BCAL Diagnostics Limited (AU:BDX)

ASX:BDX

BDX

BCAL Diagnostics Limited

RESEARCH TOOLSreports

BCAL Diagnostics Limited (BDX) Price & Analysis

Compare

7 Followers

BDX Stock Chart & Stats

AU$0.10

>-AU$0.01(-2.06%)

At close: Jan 09 4:00 PM EST

AU$0.10

>-AU$0.01(-2.06%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.16

Previous CloseN/A

Volume98.04K

Average Volume (3M)421.90K

Market Cap

AU$37.79M

Enterprise ValueAU$38.24M

Total Cash (Recent Filing)AU$3.33M

Total Debt (Recent Filing)AU$3.78M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding368,683,300

10 Day Avg. Volume534,308

30 Day Avg. Volume421,904

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)3.64

Price to Sales (P/S)1047.06

P/FCF Ratio-3.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Manageable LeverageA debt-to-equity ratio of 0.38 indicates moderate leverage and limited reliance on external debt. Over the next several months this balance-sheet posture preserves financial flexibility for R&D and commercialization milestones, lowering near-term refinancing and solvency risk compared with highly leveraged peers.

Equity Funding CushionAn equity ratio of ~62.8% shows a capital structure skewed toward equity financing, providing a buffer to absorb losses and support continued clinical development. This structural capital mix reduces immediate liquidity pressure and helps sustain operations through development phases without immediate large debt repayments.

Clear Clinical Focus & IPA focused business model centered on breast‑cancer blood tests and related IP targets a large, enduring market with structural demand for earlier detection. If clinical validation and regulatory steps progress, the lab‑based assay model can scale recurring revenue and create durable competitive barriers via proprietary diagnostics.

Bears Say

Severe Revenue CollapseA nearly 100% revenue decline signals loss of commercial traction or discontinued revenues and undermines the business model's ability to generate sustainable sales. Over a 2–6 month horizon this heightens reliance on financing, raises execution risk for commercialization, and weakens negotiating leverage with partners.

Deep Negative ProfitabilityAn extreme negative net margin reflects substantial operating losses relative to revenue and persistent cost structure issues. Such deep losses are structurally dilutive, force repeated capital raises or cost restructuring, and impede reinvestment in trials or commercialization that are essential for long‑term value creation.

Negative Operating Cash FlowConsistently negative operating and free cash flow indicate the company is not funding operations internally and is dependent on external capital. This structural cash shortfall increases financing and dilution risk, potentially constraining development timelines and commercialization efforts in the medium term.

BCAL Diagnostics Limited News

BCAL speeds national rollout of Avantect cancer blood tests

BCAL Diagnostics Limited ( ($AU:BDX) ) has provided an update. BCAL Diagnostics has expanded national access to its...

3d ago

BDX

BCAL Director Jayne Shaw Increases Shareholding via On‑Market Purchase

BCAL Diagnostics Limited ( ($AU:BDX) ) has issued an announcement. BCAL Diagnostics has disclosed a change in the...

9d ago

BDX

BCAL Director Jayne Shaw Increases Shareholding Via On-Market Purchase

BCAL Diagnostics Limited ( ($AU:BDX) ) has issued an update. BCAL Diagnostics has reported a change in the...

10d ago

BDX

BCAL director Jayne Shaw boosts stake with on-market share purchase

BCAL Diagnostics Limited ( ($AU:BDX) ) has provided an announcement. BCAL Diagnostics director Jayne Shaw has increased her...

12d ago

BDX

BCAL Diagnostics Issues New Shares to Service Provider Under Cleansing Notice

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has issued 615,651 new...

23d ago

BDX

BCAL Diagnostics Issues Shares to Settle Service Provider Invoice

BCAL Diagnostics Limited ( ($AU:BDX) ) has shared an update. BCAL Diagnostics has applied to the ASX for...

23d ago

BDX

BCAL Director Jayne Shaw Increases Shareholding via On-Market Purchase

An update from BCAL Diagnostics Limited ( ($AU:BDX) ) is now available. BCAL Diagnostics has disclosed a change...

1M ago

BDX

BCAL Diagnostics Accelerates Commercial Rollout of Cancer Blood Tests and Targets Broader Market for BREASTESTplus

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has commenced the commercial...

2M ago

BDX

BCAL Diagnostics Ramps Up Cancer Test Launches as Clinical Data and Funding Strengthen Growth Plans

The latest update is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has completed preparations for...

2M ago

BDX

BCAL Diagnostics to Launch Nationwide Cancer Detection Tests in Australia

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics Limited has announced the launch of...

4M ago

BDX

BDX FAQ

What was BCAL Diagnostics Limited’s price range in the past 12 months?

BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.

What is BCAL Diagnostics Limited’s market cap?

BCAL Diagnostics Limited’s market cap is AU$37.79M.

When is BCAL Diagnostics Limited’s upcoming earnings report date?

BCAL Diagnostics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 157 days.

How were BCAL Diagnostics Limited’s earnings last quarter?

BCAL Diagnostics Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.

Is BCAL Diagnostics Limited overvalued?

According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BCAL Diagnostics Limited pay dividends?

BCAL Diagnostics Limited does not currently pay dividends.

What is BCAL Diagnostics Limited’s EPS estimate?

BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BCAL Diagnostics Limited have?

BCAL Diagnostics Limited has 368,683,300 shares outstanding.

What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?

BCAL Diagnostics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.

Which hedge fund is a major shareholder of BCAL Diagnostics Limited?

Currently, no hedge funds are holding shares in AU:BDX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

BCAL Diagnostics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-164.22%

Trailing 12-Months

Asset Growth

-37.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BCAL Diagnostics Limited

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.